DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Price TJ. et al.
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.
Lancet Oncol 2014;
15: 569-579
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.